CATHERINE MELIN: Open Payments
NPI 1689193104 · NASHVILLE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$762 in 41 payments from 12 companies in 2025. Trend: 2023 $801 · 2024 $878 · 2025 $762
Food & beverage: $762
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $284 |
| AstraZeneca Pharmaceuticals LP | 6 | $104 |
| Lilly USA, LLC | 4 | $80 |
| GlaxoSmithKline, LLC. | 2 | $59 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $59 |
| Amgen Inc. | 3 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| ABBVIE INC. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $18 |
Products named: Wegovy, JARDIANCE, TRELEGY ELLIPTA, AIRSUPRA, MOUNJARO, Rybelsus, Ozempic, GEMTESA.
Industry payments across NC — which companies pay providers there.
